Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.

        Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.  October 23, 2024Company Announcement No. 29Reponex Pharmaceuticals A/S (Reponex) today announced that the Japan Patent Office has granted a patent for patent application No. 7562413. The patent concerns Reponex's innovative treatment method for eliminating biofilms, which prevent the body's immune system...

Hørsholm, 23/10/2024 (informazione.it - comunicati stampa - servizi)

Attachment